Cargando…
Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study
BACKGROUND: A precipitous decline in health status among people recently released from prison is common. In Victoria, Australia, opioid agonist treatment (OAT) in the community involves frequent contact with primary care, potentially facilitating broader use of primary healthcare services. Among a c...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044112/ https://www.ncbi.nlm.nih.gov/pubmed/36978089 http://dx.doi.org/10.1186/s12954-023-00773-2 |
_version_ | 1784913293895270400 |
---|---|
author | Curtis, Michael Wilkinson, Anna L. Dietze, Paul Stewart, Ashleigh C. Kinner, Stuart A. Winter, Rebecca J. Aitken, Campbell Walker, Shelley J. Cossar, Reece D. Butler, Tony Stoové, Mark |
author_facet | Curtis, Michael Wilkinson, Anna L. Dietze, Paul Stewart, Ashleigh C. Kinner, Stuart A. Winter, Rebecca J. Aitken, Campbell Walker, Shelley J. Cossar, Reece D. Butler, Tony Stoové, Mark |
author_sort | Curtis, Michael |
collection | PubMed |
description | BACKGROUND: A precipitous decline in health status among people recently released from prison is common. In Victoria, Australia, opioid agonist treatment (OAT) in the community involves frequent contact with primary care, potentially facilitating broader use of primary healthcare services. Among a cohort of men who injected drugs regularly pre-imprisonment, we estimated differences in rates of primary healthcare use and medication dispensation between people who did and did not receive OAT post-release. METHODS: Data came from the Prison and Transition Health Cohort Study. Three-month post-release follow-up interviews were linked with primary care and medication dispensation records. Generalised linear models were fit with one exposure (OAT: none/partial/complete) for 13 outcomes relating to primary healthcare use, pathology testing, and medication dispensation, adjusted for other covariates. Coefficients were reported as adjusted incidence rate ratios (AIRR). RESULTS: Analyses included 255 participants. Compared to no OAT use, both partial and complete OAT use were associated with increased rates of standard (AIRR: 3.02, 95%CI: 1.88–4.86; AIRR: 3.66, 95%CI: 2.57–5.23), extended (AIRR: 2.56, 95%CI: 1.41–4.67; AIRR: 2.55, 95%CI: 1.60–4.07) and mental health-related (AIRR: 2.71, 95%CI: 1.42–5.20; AIRR: 2.27, 95%CI: 1.33–3.87) general practitioner (GP) consultations, total medication (AIRR: 1.88, 95%CI: 1.19–2.98; AIRR: 2.40, 95%CI: 1.71–3.37), benzodiazepine (AIRR: 4.99, 95%CI: 2.81–8.85; AIRR: 8.30, 95%CI: 5.28–13.04) and gabapentinoid (AIRR: 6.78, 95%CI: 3.34–13.77; AIRR: 4.34, 95%CI: 2.37–7.94) dispensations, respectively. Partial OAT use was also associated with increased after-hours GP consultations (AIRR: 4.61, 95%CI: 2.24–9.48) and complete OAT use? with increased pathology utilisation (e.g. haematological, chemical, microbiological or immunological tissue/sample testing; AIRR: 2.30, 95%CI: 1.52–3.48). CONCLUSION: We observed higher rates of primary healthcare use and medication dispensation among people who reported partial and complete OAT use post-release. Findings suggest that access to OAT post-release may have a collateral benefit in supporting broader health service utilisation, underscoring the importance of retention in OAT after release from prison. |
format | Online Article Text |
id | pubmed-10044112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100441122023-03-28 Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study Curtis, Michael Wilkinson, Anna L. Dietze, Paul Stewart, Ashleigh C. Kinner, Stuart A. Winter, Rebecca J. Aitken, Campbell Walker, Shelley J. Cossar, Reece D. Butler, Tony Stoové, Mark Harm Reduct J Research BACKGROUND: A precipitous decline in health status among people recently released from prison is common. In Victoria, Australia, opioid agonist treatment (OAT) in the community involves frequent contact with primary care, potentially facilitating broader use of primary healthcare services. Among a cohort of men who injected drugs regularly pre-imprisonment, we estimated differences in rates of primary healthcare use and medication dispensation between people who did and did not receive OAT post-release. METHODS: Data came from the Prison and Transition Health Cohort Study. Three-month post-release follow-up interviews were linked with primary care and medication dispensation records. Generalised linear models were fit with one exposure (OAT: none/partial/complete) for 13 outcomes relating to primary healthcare use, pathology testing, and medication dispensation, adjusted for other covariates. Coefficients were reported as adjusted incidence rate ratios (AIRR). RESULTS: Analyses included 255 participants. Compared to no OAT use, both partial and complete OAT use were associated with increased rates of standard (AIRR: 3.02, 95%CI: 1.88–4.86; AIRR: 3.66, 95%CI: 2.57–5.23), extended (AIRR: 2.56, 95%CI: 1.41–4.67; AIRR: 2.55, 95%CI: 1.60–4.07) and mental health-related (AIRR: 2.71, 95%CI: 1.42–5.20; AIRR: 2.27, 95%CI: 1.33–3.87) general practitioner (GP) consultations, total medication (AIRR: 1.88, 95%CI: 1.19–2.98; AIRR: 2.40, 95%CI: 1.71–3.37), benzodiazepine (AIRR: 4.99, 95%CI: 2.81–8.85; AIRR: 8.30, 95%CI: 5.28–13.04) and gabapentinoid (AIRR: 6.78, 95%CI: 3.34–13.77; AIRR: 4.34, 95%CI: 2.37–7.94) dispensations, respectively. Partial OAT use was also associated with increased after-hours GP consultations (AIRR: 4.61, 95%CI: 2.24–9.48) and complete OAT use? with increased pathology utilisation (e.g. haematological, chemical, microbiological or immunological tissue/sample testing; AIRR: 2.30, 95%CI: 1.52–3.48). CONCLUSION: We observed higher rates of primary healthcare use and medication dispensation among people who reported partial and complete OAT use post-release. Findings suggest that access to OAT post-release may have a collateral benefit in supporting broader health service utilisation, underscoring the importance of retention in OAT after release from prison. BioMed Central 2023-03-28 /pmc/articles/PMC10044112/ /pubmed/36978089 http://dx.doi.org/10.1186/s12954-023-00773-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Curtis, Michael Wilkinson, Anna L. Dietze, Paul Stewart, Ashleigh C. Kinner, Stuart A. Winter, Rebecca J. Aitken, Campbell Walker, Shelley J. Cossar, Reece D. Butler, Tony Stoové, Mark Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study |
title | Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study |
title_full | Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study |
title_fullStr | Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study |
title_full_unstemmed | Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study |
title_short | Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study |
title_sort | is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? a prospective cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044112/ https://www.ncbi.nlm.nih.gov/pubmed/36978089 http://dx.doi.org/10.1186/s12954-023-00773-2 |
work_keys_str_mv | AT curtismichael isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy AT wilkinsonannal isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy AT dietzepaul isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy AT stewartashleighc isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy AT kinnerstuarta isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy AT winterrebeccaj isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy AT aitkencampbell isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy AT walkershelleyj isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy AT cossarreeced isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy AT butlertony isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy AT stoovemark isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy |